Categories
Change Password!
Reset Password!
Taking NSAIDs after 60? Study warns of increased G...
Tegoprazan emerges as fast-acting alternative to P...
A large study has positioned tegoprazan, a potassium-competitive acid blocker (PCAB), as a next-generation therapy for gastroesophageal reflux di...
Low-dose aspirin raises gastric and duodenal ulcer...
A large population-based analysis of over 220,000 volunteers has revealed that low-dose aspirin initiation is connected with increased risk of ga...
High-dose vs. conventional therapy for H. pylori e...
Optimizing Helicobacter pylori (H. pylori) eradication therapy is fundamental in the era of rising antibiotic resistance.
Global PPI use hits 25%: Study flags rising long-t...
A large-scale systematic review assessing global trends in proton pump inhibitor (PPI) use has revealed that these acid-suppressing drugs are use...
Reflux oesophagitis risk factors: The hidden role...
Reflux oesophagitis, a common form of gastroesophageal reflux disease (GERD), is frequently diagnosed in both gastroenterology and primary care s...
Tradipitant
Tradipitant is a centrally acting antiemetic approved by the Food and Drug Administration (FDA) on 30 December 2025 for the prevention of motion...
Nitazoxanide-based regimens outperform standard tr...
A novel systematic review and meta-analysis of randomized controlled trials suggests that nitazoxanide (NTZ)-based triple therapy may offer super...
Non-invasive biomarkers in liver fibrosis and tran...
Liver fibrosis, a progressive pathological condition, is marked by abnormally high accumulation of extracellular matrix components, ultimately le...
PCABs offer superior clinical outcomes across majo...
Potassium-competitive acid blockers (PCABs) may outperform traditional proton pump inhibitors (PPIs) in the management of major acid-related diso...
